

# Medicines Shortages – Causation and Approaches to Improvements The Clinical Needs

EAHP Academy Seminar  
19 – 21 October 2018, Warsaw, Poland

Nenad Miljković  
Hospital Pharmacist  
Public-health Professional

# Conflict of Interest

- Nothing to disclose





# Outline

- Real cases
- Clinical needs vs clinical risks
- Clinical risk management
- Antimicrobial shortages
- Life-saving medicine shortages

# Case: Morphine Injection Shortage

- When hydromorphone is introduced as an alternative:
  - An IV of HYDRORmorphone prescribed at the intended dose to replace morphine resulting in the death of two patients
  - A HYDRORmorphone 0.5 mg IV was to be substituted for morphine 4 mg IV, but a HYDRORmorphone 4 mg IV was given in error
  - A patient switched from a morphine 6 mg IV to HYDRORmorphone but no change in the dose. The patient received several 6 mg doses, which required naloxone administration and increased the length of hospitalization

**CLINICAL NEED (how much? how potent? how long?)**

# Case: No Propofol on the Horizon ...

- Methohexital was given as an alternative agent for deep sedation instead of propofol:
  - Unfamiliarity with diluting and dosing methohexital resulted in the death of a patient
- A paralyzed, ventilated patient received no sedation since propofol was not available and an alternative drug was never prescribed
- Prolonged hospitalization from intractable post-op nausea and vomiting has occurred with alternative sedation agents
- Inadequate sedation with benzodiazepines led to agitation and self-extubation where one patient bit through her tongue

**CLINICAL NEED (how much? how potent? how long?)**

**How agitated is the patient?**

**Postoperative nausea?**

**Vomiting related sedative?**

# What to Bare in Mind - Thiopental

- Alternative medicines or techniques
- Thiopental sodium
- HEED CAUTION when used as an alternative to propofol!
- Not an anti-emetic
- Does not suppress laryngeal and airway reflexes as effectively as propofol
- Causes severe tissue necrosis if extravasated in intra-arterial injection crystals form causing distal ischaemia
- Longer elimination half-time; unsuitable for rapid recovery after infusion or accumulated boluses
- CONTRA-INDICATED in patients with porphyria or barbiturate allergy



# What to Bare in Mind - Etomidate

HEED CAUTION when used as an alternative to propofol:

- A glucocorticoid should be given to cover adrenal suppression lasting up to 24 hours after a single dose
- Not an anti-emetic
- Involuntary movements, rigidity, coughing, hiccoughing and larygospasm much more likely than with propofol (50% vs 10%)
- Pain on injection, venous thrombosis and thrombophlebitis are particularly problematic
- Lethal as a sedative infusion for critically-ill patients

# Key Messages

- Substitution needs to take into account individual patient-clinical needs as much as possible
- Dosing, reconstitution, route of administration should not be conducted automatically compared to the original treatment
- If a substitute is not the optimal option, additional monitoring should be a must after an alternative is introduced to a patient
- Timing plays a crucial role in substituting a medicine depending on the disease and the patient's clinical condition

# Case: Piperacilin/Tazobactam Shortage

- What should we look for when determining an alternative medicine?
  - antibiotic spectrum of activity
  - formulary cost
  - local bacterial / susceptibility patterns
- What do we need to do when the physician wants to switch to cefepime (+/-metronidazole) or a formulary carbapenem?
  - Provide corresponding information taking into account clinical needs

# But What if There Is no Cefepime?

- Alternatives to cefepime also exist but have significant limitations:
  - Ceftriaxone offers good Gram-positive and Gram-negative activity, but does not cover *P. aeruginosa*
  - Ceftazidime offers good Gram-negative activity, including *Pseudomonas* spp, but also has the drawback of poor Gram-positive activity. It also lacks anaerobic activity and might lead to a higher incidence of ceftazadime-resistant *Pseudomonas* spp

# But What if There Is no Cefepime?

- Carbapenems can provide a similar spectrum of activity to piperacillin/tazobactam
- There are 2 major limitations in the practice of substituting piperacillin/tazobactam for carbapenems:
  - Promoted development of most multi-drug resistant organisms, such as carbapenem-resistant Enterobacteriaceae (CRE), associated with high mortality, nosocomial-outbreaks, and poor patient outcomes
  - More costly than piperacillin/tazobactam.

# Flumazenil - Who gets it and Who Doesn't?

Key changes include:

- Physicians should be aware of the shortage of flumazenil (0.1 mg/mL 5 mL injection)
- Conserve flumazenil injection for those requiring mechanical ventilation except for the contraindications as indicated below:
- Accidental pediatric ingestion with compromised airway and breathing
- Intentional self-poisoning with present compromised airway and breathing when skills and equipment to intubate are not readily available
- Reversal of benzodiazepine sedation in short diagnostic and therapeutic procedures

COMMENTARY

# Prince didn't need to die; an opioid antidote was available in naloxone

Those at risk of overdose should be given training and access to this remedy, which is a simple nose spray.

By Evan Rausch | APRIL 22, 2017 — 12:45AM



I

# Naloxone 0.4 mg in 1 ml

Clinical Indications - Complete or partial reversal of opioid sedation, including respiratory depression

Alternative drugs or techniques:

1. Naltrexone
  2. Buprenorphine
- Naloxone has an extremely high affinity for  $\mu$ -opioid receptors and can produce rapid onset of withdrawal symptoms if not carefully titrated to effect
  - Naltrexone is structurally similar but has a slightly increased affinity for  $\kappa$ -opioid receptors over naloxone, which can only be administered externally
  - Buprenorphine is a partial agonist and could be used to reduce but not reverse  $\mu$ -receptor stimulation



# Clinical Need vs Clinical Risk

## Clinical Need

“The input needed to reduce risk and achieve predicted outcomes, which approximates to the amount of clinical input needed.”

## Clinical Risk

“The degree to which foreseeable harm can be managed by your intervention.”

*Kate Malcomess,  
the Care Aims Intended Outcomes Framework Founder*

# Clinical Need – met or unmet?

If NO  
handling risks

- Clinical risks divided into two areas:
- medication errors
- adverse patient outcomes

The potential harm of the substitute will depend on the clinical situation/clinical need we NEED to assess

# Clinical Need - Delay or Providing a Substitute?

- state of the disease
- medicine
- length of time of the delay
- clinically significant delay (vaccines vs antimicrobials?)

# Unmet Clinical Needs with Emerging Clinical Risks

## Chemotherapy

Uncertain outcomes / cure

---

- Delay in treatment
- Inferior outcomes
- Omitted / reduced doses; rationing / substitution not supported by evidence

## Antimicrobials

Toxicity / Safety profile

---

- Poor outcomes
- Death / decreased therapeutic efficacy

## Anesthetics

Longer anesthesia / Recovery times

---

- Hypotension, Apnea
- Aspiration / prolonged mechanical ventilation / nausea / vomiting

# Clinical Needs Assessment

- What is clinical needs assessment?

‘A process by which information is gathered regarding the scope and potential impact of gaps or deficiencies in the current delivery and practice of health care’


Weigl et al. 2012

# Risk Assessment-Why do we Consider Risks?



- Risk associated with the unavailability of a medicine
- Risk associated with replacement medicines

# Critical Points to be Considered



# Clinical Risk Management

Step 1- Establish the context

Step 2- Identify risks

Step 3- Analyse risks

Step 4- Evaluate risks

Step 5- Reduce / control / eliminate risks



# Step 1: Establishing the Context


- Key questions?
- **Has the strategic and organisational context been clearly defined?**
- *Do we know how the system works when a prescriber / health care professional finds out that there is a shortage?*
- **Has the clinical risk evaluation criteria been established?**
- *Do we know on what grounds (indicators) we are assessing risks from a shortage?*
- **Has the clinical risk management framework been established and resources assigned?**
- *Do we know what methodology we are using to quickly assess emerging risks from a shortage?*

## Step 2: Clinical Risk Identification

What if...  
But what if...  
And then ...

- Identify the likelihood and consequence of actual and potential clinical risks and determine which clinical risks need to be managed and treated as a priority


# Step 2: Clinical Risk Identification



# Step 3: Clinical Risk Analysis

- Determine the potential consequences and impact of the worst case clinical risks should they occur
- Identify the factors which may increase or decrease clinical risk
- Select the most suitable risk analysis tool and calculate the level of clinical risk


# Step 4: Clinical Risk Evaluation



Decide if a clinical risk is acceptable or whether it requires actions to reduce the level of risk

Develop a prioritised list of clinical risks

# Step 5: Selection of Options for Treating Clinical Risks



# Key Messages

## Patients

- Have the right to expect healthcare professionals to be responsible for their care and treatment to be effective regardless of medicine shortages

## Health-care professionals

- Develop a deeper understanding of the patients' clinical needs
- Making decisions regarding medicine substitution within a multidisciplinary team

CONDITIONS

## Drug Shortages: The Scary Reality of a World Without Meds

## Drug shortages in U.S. emergency rooms on the rise

HUB



### Health experts offer recommendations to combat shortages of lifesaving drugs

Consensus statement calls for proactive strategy focused on prevention

## Recall of Opioid Overdose Drug is the Latest in a Series of Shortages and Backorders



NATIONAL HEALTHCARE

## 'Patients will die if they don't fix this': Hospitals rationing, stockpiling first-line antibiotics amid drug shortage

TREATMENTS

## Critical Drugs For Hospital ERs Remain In Short Supply

May 2, 2016 - 4:17 PM ET

## 'Unorderly' Brexit risks shortage of life-saving drugs




# A Hospital Pharmacy Reality



A white board showed the drugs in short supply at the University of Utah Hospital in Salt Lake City in 2011.

Jim Urquhart/AP


# Antimicrobial Shortages-Europe



# Antimicrobial Shortages

Medicines	Resolved Shortage Time in Days (2001-2013)
With injectable administration	250
Without injectable administration	129
With available alternatives	262
Without available alternatives	149.5
Broad spectrum	232
Narrow spectrum	199.5


# Antimicrobial Shortages



**Figure 2.** Drug shortages by drug class, 2001–2013.

Source: University of Utah Drug Information Service database

# Rise of Antimicrobial Shortages



# Antimicrobial Shortages


Broad-spectrum agents-injectable drugs

Medicines with no alternative sources


Medicines used on pathogens with limited alternative treatment options or in paediatric patients

Medicines used to treat highly drug-resistant pathogens  
(including MRSA, CRE, and Pseudomonas)

# Antimicrobials Shortages-Implications for the Clinical Management



# Antimicrobial Shortages





# Do you have Gentamicin in your Pharmacy?

Maybe  
tobramycin  
or  
amikacin  
or  
streptomycin  
BUT.....

- Enterococcus species are intrinsically resistant to tobramycin and amikacin
- a substantial risk for ototoxicity and vestibular disturbance
- assessment of streptomycin serum concentrations requires special laboratory testing
- increased use of streptomycin could rapidly end in a 'rebound' shortage



# New Cases on the Horizon

## IV vancomycin:

Alternative agents: teicoplanin, daptomycin, linezolid & ceftaroline

Risk associated with alternatives:

- Teicoplanin – similar to vancomycin
- Daptomycin – increase CK
- Linezolid – myelosuppression, optic and peripheral neuropathy
- Ceftaroline – neutropenia if treated > 2-3 weeks

# New Cases on the Horizon

## IV aciclovir:

Alternative agents: ganciclovir, foscarnet & cidofovir

Risk associated with alternatives:

- Ganciclovir – bone marrow suppression
- Foscarnet – decreased renal function and electrolyte abnormalities
- Cidofovir – nephrotoxicity

# Emergency Department Medicines



# Case: Succinylcholine in Short Supply

Rocuronium may be used but ...

Alternative paralytics may be:


- less effective than succinylcholine

- lead to prolonged paralysis

- suboptimal intubating

- Increased the risk of complications

# Delays



# Compounding Issues

Calculating differences between dozes must take into account

Microbial contamination of compauded products

Substandard production due to constraints in small-scale pharmacy compounding

Improper labeling

# Compromised Sterility and Infectious Complications

Example: 50-mL vials of propofol were reused for multiple patients to conserve the medication, which resulted in the transmission of hepatitis C virus between patients

- Sterile single-use vials of injectable products penetrated multiple times to conserve medication despite violating labeling recommendations



- Improper use can lead to disease transmission between patients, including hepatitis B, C, and the human immunodeficiency virus



# Key Messages

- Keep local inventory of critical antibacterial agents
- Anticipate the need for alternatives
- Create contingency plans
- Maintain a multidisciplinary antimicrobial stewardship plan
- Create guidelines
- Developing protocols
- Establish an interdisciplinary medicine shortage task force

THANK YOU FOR YOUR ATTENTION

